

**SCHEDULE OF INVESTMENTS**

March 31, 2024

**BIOTECHNOLOGY FUND**

	SHARES	VALUE		SHARES	VALUE
<b>COMMON STOCKS<sup>†</sup> - 99.6%</b>					
<b>BIOTECHNOLOGY - 73.8%</b>					
Amgen, Inc.	24,732	\$ 7,031,802			
Regeneron Pharmaceuticals, Inc.*	5,792	5,574,742			
Vertex Pharmaceuticals, Inc.*	11,049	4,618,592			
Gilead Sciences, Inc.	57,387	4,203,598			
Corteva, Inc.	61,639	3,554,721			
Moderna, Inc.*	31,852	3,394,149			
Biogen, Inc.*	14,196	3,061,083			
Illumina, Inc.*	18,761	2,576,260			
Anylam Pharmaceuticals, Inc.*	15,959	2,385,073			
BioMarin Pharmaceutical, Inc.*	25,837	2,256,604			
Royalty Pharma plc — Class A	71,829	2,181,447			
Sarepta Therapeutics, Inc.*	15,022	1,944,748			
Incyte Corp.*	31,182	1,776,439			
United Therapeutics Corp.*	7,578	1,740,818			
Legend Biotech Corp. ADR*	30,111	1,688,926			
Argenx SE ADR*	4,196	1,652,049			
Cytokinetics, Inc.*	21,997	1,542,210			
Exelixis, Inc.*	63,269	1,501,373			
BioNTech SE ADR*	15,100	1,392,975			
CRISPR Therapeutics AG <sup>*1</sup>	20,413	1,391,350			
Intra-Cellular Therapies, Inc.*	20,089	1,390,159			
Apellis Pharmaceuticals, Inc.*	22,299	1,310,735			
Ionis Pharmaceuticals, Inc.*	29,419	1,275,314			
Halozyne Therapeutics, Inc.*	30,345	1,234,435			
REVOLUTION Medicines, Inc.*	38,269	1,233,410			
Blueprint Medicines Corp.*	12,634	1,198,461			
Roivant Sciences Ltd. <sup>*1</sup>	112,163	1,182,198			
Bridgebio Pharma, Inc.*	37,164	1,149,111			
Insmed, Inc.*	40,289	1,093,041			
Ultragenyx Pharmaceutical, Inc.*	21,540	1,005,703			
Amicus Therapeutics, Inc.*	85,233	1,004,045			
Axsome Therapeutics, Inc.*	12,544	1,001,011			
Iovance Biotherapeutics, Inc.*	66,996	992,881			
Prothena Corporation plc*	39,542	979,455			
Arrowhead Pharmaceuticals, Inc.*	33,426	955,984			
Guardant Health, Inc.*	41,004	845,912			
Intellia Therapeutics, Inc.*	30,368	835,424			
Beam Therapeutics, Inc.*	23,627	780,636			
Immunovant, Inc.*	24,151	780,319			
PTC Therapeutics, Inc.*	26,205	762,303			
TG Therapeutics, Inc.*	48,615	739,434			
ACADIA Pharmaceuticals, Inc.*	39,352	727,618			
Dynavax Technologies Corp.*	55,099	683,779			
Krystal Biotech, Inc.*	3,638	647,309			
Akero Therapeutics, Inc.*	20,468	517,022			
Sage Therapeutics, Inc.*	26,796	502,157			
Novavax, Inc. <sup>*1</sup>	83,168	397,543			
<b>Total Biotechnology</b>		<b>80,694,358</b>			
<b>PHARMACEUTICALS - 20.7%</b>					
AbbVie, Inc.	54,865	9,990,916			
AstraZeneca plc ADR	43,805	2,967,789			
Neurocrine Biosciences, Inc.*	14,843	2,047,147			
Viatis, Inc.	170,310	2,033,501			
Jazz Pharmaceuticals plc*	12,556	\$ 1,511,993			
Alkermes plc*	55,814	1,510,885			
Vaxcyte, Inc.*	20,625	1,408,894			
Ironwood Pharmaceuticals, Inc. — Class A*	67,889	591,313			
Madrigal Pharmaceuticals, Inc.*	2,065	551,438			
<b>Total Pharmaceuticals</b>		<b>22,613,876</b>			
<b>HEALTHCARE-PRODUCTS - 3.9%</b>					
Exact Sciences Corp.*	29,095	2,009,301			
Natera, Inc.*	19,319	1,766,916			
Pacific Biosciences of California, Inc.*	125,198	469,492			
<b>Total Healthcare-Products</b>		<b>4,245,709</b>			
<b>HEALTHCARE-SERVICES - 1.2%</b>					
Medpace Holdings, Inc.*	3,359	1,357,540			
<b>Total Common Stocks</b> (Cost \$56,457,113)					<b>108,911,483</b>
				<b>FACE</b>	
				<b>AMOUNT</b>	
<b>REPURCHASE AGREEMENTS<sup>††2</sup> - 0.2%</b>					
J.P. Morgan Securities LLC issued 03/28/24 at 5.31% due 04/01/24	\$ 138,611	138,611			
BofA Securities, Inc. issued 03/28/24 at 5.31% due 04/01/24	53,312	53,312			
Barclays Capital, Inc. issued 03/28/24 at 5.30% due 04/01/24	48,322	48,322			
<b>Total Repurchase Agreements</b> (Cost \$240,245)					<b>240,245</b>
				<b>SHARES</b>	
<b>SECURITIES LENDING COLLATERAL<sup>†3</sup> - 1.6%</b>					
<b>Money Market Fund</b>					
First American Government Obligations Fund - Class X, 5.23% <sup>4</sup>	1,757,813	1,757,813			
<b>Total Securities Lending Collateral</b> (Cost \$1,757,813)					<b>1,757,813</b>
<b>Total Investments - 101.4%</b> (Cost \$58,455,171)					<b>\$ 110,909,541</b>
<b>Other Assets &amp; Liabilities, net - (1.4)%</b>					<b>(1,533,451)</b>
<b>Total Net Assets - 100.0%</b>					<b>\$ 109,376,090</b>

**BIOTECHNOLOGY FUND**

\* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

<sup>1</sup> All or a portion of this security is on loan at March 31, 2024.

<sup>2</sup> Repurchase Agreements.

<sup>3</sup> Securities lending collateral.

<sup>4</sup> Rate indicated is the 7-day yield as of March 31, 2024.

ADR — American Depositary Receipt

plc — Public Limited Company